MX2023012727A - Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto. - Google Patents
Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto.Info
- Publication number
- MX2023012727A MX2023012727A MX2023012727A MX2023012727A MX2023012727A MX 2023012727 A MX2023012727 A MX 2023012727A MX 2023012727 A MX2023012727 A MX 2023012727A MX 2023012727 A MX2023012727 A MX 2023012727A MX 2023012727 A MX2023012727 A MX 2023012727A
- Authority
- MX
- Mexico
- Prior art keywords
- depressive disorder
- major depressive
- disubstituted
- postpartum depression
- treating major
- Prior art date
Links
- 201000009916 Postpartum depression Diseases 0.000 title abstract 3
- 208000024714 major depressive disease Diseases 0.000 title abstract 3
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 230000036506 anxiety Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación se refiere a métodos para tratar el trastorno depresivo mayor (MDD) con ansiedad elevada en un sujeto en necesidad del mismo, mediante la administración de una cantidad terapéuticamente efectiva del Compuesto (1), o una sal farmacéuticamente aceptable del mismo. La divulgación también se refiere a métodos para tratar la depresión posterior al parto (PPD) con ansiedad elevada en un sujeto en necesidad del mismo, mediante la administración de una cantidad terapéuticamente efectiva del Compuesto (1), o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181743P | 2021-04-29 | 2021-04-29 | |
| US202163197025P | 2021-06-04 | 2021-06-04 | |
| US202163210810P | 2021-06-15 | 2021-06-15 | |
| US202163239096P | 2021-08-31 | 2021-08-31 | |
| US202163285812P | 2021-12-03 | 2021-12-03 | |
| US202163289520P | 2021-12-14 | 2021-12-14 | |
| US202163289506P | 2021-12-14 | 2021-12-14 | |
| US202263298601P | 2022-01-11 | 2022-01-11 | |
| PCT/US2022/026920 WO2022232504A1 (en) | 2021-04-29 | 2022-04-29 | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012727A true MX2023012727A (es) | 2023-11-08 |
Family
ID=81748925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012727A MX2023012727A (es) | 2021-04-29 | 2022-04-29 | Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240216395A1 (es) |
| EP (1) | EP4329770A1 (es) |
| JP (2) | JP2024515829A (es) |
| KR (1) | KR20240006026A (es) |
| AU (1) | AU2022266680A1 (es) |
| BR (1) | BR112023022264A2 (es) |
| CA (1) | CA3218072A1 (es) |
| IL (1) | IL307991A (es) |
| MX (1) | MX2023012727A (es) |
| TW (1) | TW202308654A (es) |
| WO (1) | WO2022232504A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122021022560B1 (pt) | 2012-08-21 | 2022-08-09 | Sage Therapeutics, Inc | Kit, método de preparação de dosagens e método de ajuste da quantidade de diluentes e ou alopregnanolona em dispositivo de liberação |
| IL310348A (en) | 2013-04-17 | 2024-03-01 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| SMT202000276T1 (it) | 2014-11-27 | 2020-07-08 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| TWI854445B (zh) | 2016-08-23 | 2024-09-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL310348A (en) | 2013-04-17 | 2024-03-01 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| TWI854445B (zh) | 2016-08-23 | 2024-09-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| WO2019241442A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| AU2019397565A1 (en) * | 2018-12-14 | 2021-07-08 | Praxis Precision Medicines, Inc. | Methods for the treatment of depression |
| IL299829A (en) | 2020-07-20 | 2023-03-01 | Sage Therapeutics Inc | Formulations of 19-NOR C3,3-dimer C21-N-pyrazolyl steroid and methods of using them |
| AU2023220976A1 (en) * | 2022-02-16 | 2024-09-05 | Sage Therapeutics, LLC | Neuroactive steroids for treatment of cns-related disorders |
-
2022
- 2022-04-29 MX MX2023012727A patent/MX2023012727A/es unknown
- 2022-04-29 CA CA3218072A patent/CA3218072A1/en active Pending
- 2022-04-29 AU AU2022266680A patent/AU2022266680A1/en active Pending
- 2022-04-29 JP JP2023566514A patent/JP2024515829A/ja active Pending
- 2022-04-29 US US18/557,691 patent/US20240216395A1/en active Pending
- 2022-04-29 KR KR1020237040558A patent/KR20240006026A/ko active Pending
- 2022-04-29 WO PCT/US2022/026920 patent/WO2022232504A1/en not_active Ceased
- 2022-04-29 IL IL307991A patent/IL307991A/en unknown
- 2022-04-29 TW TW111116469A patent/TW202308654A/zh unknown
- 2022-04-29 BR BR112023022264A patent/BR112023022264A2/pt unknown
- 2022-04-29 EP EP22724335.9A patent/EP4329770A1/en active Pending
-
2025
- 2025-04-28 JP JP2025074660A patent/JP2025111701A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3218072A1 (en) | 2022-11-03 |
| IL307991A (en) | 2023-12-01 |
| WO2022232504A1 (en) | 2022-11-03 |
| TW202308654A (zh) | 2023-03-01 |
| AU2022266680A1 (en) | 2023-11-02 |
| EP4329770A1 (en) | 2024-03-06 |
| JP2025111701A (ja) | 2025-07-30 |
| US20240216395A1 (en) | 2024-07-04 |
| BR112023022264A2 (pt) | 2024-01-23 |
| KR20240006026A (ko) | 2024-01-12 |
| JP2024515829A (ja) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023012727A (es) | Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto. | |
| MX2025000166A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo | |
| MX2022006533A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo. | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| MX2023010064A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo. | |
| MX2024004332A (es) | Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos. | |
| MX2021002322A (es) | Nuevos metodos. | |
| MX2020000190A (es) | Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco. | |
| WO2019094642A8 (en) | T cell manufacturing compositions and methods | |
| BR112016000804A2 (pt) | Método para tratar hemorragia, choque e lesão cerebral | |
| MX2022000812A (es) | Metodos de tratamiento de hiperplasia suprarrenal congenita. | |
| CR20190433A (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
| MX2023010728A (es) | Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor. | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| MX2023012728A (es) | Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante. | |
| MX2021004946A (es) | Terapia combinada para tratamiento de enfermedades hematológicas. | |
| MX2025003477A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| MX2020010302A (es) | Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares. | |
| MX2020011817A (es) | Metodos para tratar el linfoma. | |
| MX2024014121A (es) | Metodos y composiciones para el tratamiento del exceso de glucocorticoides | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| MX2022007595A (es) | Triterpenoides sinteticos con sustituyentes a base de nitrogeno en c-17 y metodos de uso de los mismos. | |
| PH12017501304A1 (en) | Levodopa and carbidopa intestinal gel and method of use | |
| PH12021552572A1 (en) | Combination of chir99021 and valproic acid for treating hearing loss |